Relevium Technologies Inc.

OTC: RLLVF · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Montreal, QCReports USD

#894 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH —DQ —GM —SS 39

v0.1 · 5/100 weight · pillars only

↑ Altman-Z, listing tenure · ↓ Piotroski F, disclosure history

Methodology →

Revenue TTM

$752.8k

Rev growth YoY (TTM)

-73.2%

Net income (FY)

-$4.2M

Employees

—

Market cap

$2.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$712.3k913.6k CAD2021

Net income-$4.2M-5.4M CAD2021

Operating income-$1.2M-1.5M CAD2021

Total assets$612.3k758.9k CAD2021

Liabilities$4.6M5.7M CAD2021

Equity-$4.0M-4.9M CAD2021

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Relevium Technologies Inc. booked $712.3k in FY2021 revenue, contracting 68% year over year — slower than 86% of Healthcare companies we track, at a -587.6% net margin.

Peers · Healthcare

Ernexa Therapeutics Inc.42D Psyence Group Inc.——ProtoKinetix, Incorporated——Sonoma Pharmaceuticals, Inc.59C

Key facts

CEOAurelio Useche

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersMontreal, QC

ExchangeOTC: RLLVF

Employees—

IPO date2017-11-24

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.